Optical Tissue Identification for Myocardial Architecture

Related Clinical Trial
Follow-up Study to Monitor the Efficacy and Safety of the Occlutech® mVSD Cases A Study Evaluating the Efficacy and Safety of IV L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects The Effect of Transcatheter VSD Closure on Children’s Appetite, Hormones and Growth The Effect of Transcatheter Ventricular Septal Defect Closure on Heart Rate Variability Parameters Improving Care for Children With Congenital Heart Disease. Lifetech MFO Post-Market Clinical Follow-Up Study Evaluation of Latent Pulmonary Arterial Hypertension in Congenital Shunt Lesions A Phase I Study of Dexmedetomidine Bolus and Infusion in Corrective Infant Cardiac Surgery: Safety and Pharmacokinetics Optical Tissue Identification for Myocardial Architecture Measures to Lower the Stress Response in Pediatric Cardiac Surgery Cardiac Function After Transcatheter VSD Closure The Effect of Remote Ischemic Preconditioning on the Ischemic Reperfusion Injury in Infants With Ventricular Septal Defect and Pulmonary Hypertension A Trial to Evaluate the Safety and Efficacy of a Fully Degradable Ventricular Septal Defect (VSD) Closure Closure of Muscular Ventricular Septal Defects (VSDs) With the AMPLATZER Muscular VSD (MuVSD) Occluder – Post Approval Study The Cardiopulmonary Effect of Inhaled Beta-2-agonists on Adult Patients Born With Ventricular Septum Defects. Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery : Revised Protocol Optimal Timing for Repair of Left to Right Shunt Lesions Use of Ketamine Prior to Cardiopulmonary Bypass in Children Aberrations in Carnitine Homeostasis in Congenital Heart Disease With Increased Pulmonary Blood Flow Transcatheter Closure Versus Surgery of Perimembranous Ventricular Septal Defects Cardiopulmonary Function in Adults Born With a Ventricular Septal Defect Longterm Outcome After Ventricular Septal Defect Closure Closure of Perimembranous Ventricular Septal Defects With The AMPLATZER® Membranous VSD OCCLUDER Hybrid Closure of Congenital Heart Disease

Brief Title

Optical Tissue Identification for Myocardial Architecture

Official Title

Optical Tissue Identification for Myocardial Architecture (OPTIMA Study)

Brief Summary

      The goal of this study is to test the hypothesis that fiberoptic confocal microscopy (FCM)
      imaging during repair of common congenital heart defects is a useful adjunct for avoidance of
      conduction abnormalities.

Detailed Description

      This is an interventional randomized controlled study to investigate the use of fiberoptic
      confocal microscopy (FCM) imaging for avoidance of conduction abnormalities during repair of
      common congenital heart defects. Study results will be compared to a cohort of similar
      surgical patients following standard surgical procedures where FCM was not used. We will
      analyze pre-and postoperative ECGs to identify conduction abnormalities.

Study Phase

Phase 2

Study Type


Primary Outcome

Rate of new conduction disorders

Secondary Outcome

 Change in PR interval


Ventricular Septal Defect



Study Arms / Comparison Groups

 Non-imaging cohort
Description:  There will be no intervention for the non-imaging group. Subjects will receive standard of care for cardiac surgery.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

December 20, 2019

Completion Date

November 2022

Primary Completion Date

March 8, 2022

Eligibility Criteria

        Inclusion Criteria:

          -  Age 30 days to less than 18 years old

          -  Patients with planned surgical repair of:

          -  Ventricular septal defect (VSD)

          -  Complete atrioventricular canal (CAVC)

          -  Tetralogy of Fallot (ToF) with pulmonary stenosis

        Exclusion Criteria:

          -  Prior history of adverse reaction to fluorescein sodium

          -  Prior history of renal failure or abnormal renal function

          -  Baseline PR interval > 220 msec or 98% for age

          -  Baseline HR > 98% for age

          -  Underlying genetic syndrome associated with progressive AV block or sinus node
             dysfunction (e.g. Holt-Oram or NKX2.5)

          -  Any surgical repair that requires staging or palliation

          -  Pregnant or lactating

          -  Exclusions specific to type of surgical repair

          -  Apical muscular VSD

          -  ToF with pulmonary atresia




30 Days - 18 Years

Accepts Healthy Volunteers



Aditya K Kaza, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Secondary IDs


Responsible Party


Study Sponsor

Aditya Kaza


 National Heart, Lung, and Blood Institute (NHLBI)

Study Sponsor

Aditya K Kaza, MD, Principal Investigator, Boston Children's Hospital

Verification Date

April 2022